Quit Ozempic and Restart GLP-1 Cycling Risks: The Hidden Heart Attack Danger

# Quit Ozempic and Restart GLP-1 Cycling Risks: The Hidden Heart Attack Danger

> **Quick answer:** Stopping GLP-1 drugs like Ozempic for as little as six months raises your cardiovascular risk by 4-8% compared to continuous use — and that number climbs to 22% after two years off, according to a major 2026 study. Most people who quit plan to restart, but restarting only partially restores the protection your heart had built up. Researchers are calling this effect "metabolic whiplash," and it's a danger that most patients — and even some doctors — aren't discussing.

Three in four people who start Ozempic or Wegovy quit within a year. Most of them plan to restart. That sounds like a reasonable plan. New research published in March 2026 says it's quietly dangerous — and the quit-restart cycle known as GLP-1 cycling is creating a hidden cardiovascular crisis that nobody is talking about loudly enough.

## What the Science Actually Says About Stopping GLP-1 Drugs

The largest study to date on GLP-1 discontinuation was published March 18, 2026, in *BMJ Medicine* by researchers at Washington University School of Medicine. The study tracked 333,687 U.S. veterans with type 2 diabetes over three years — 132,551 on GLP-1 medications (semaglutide, tirzepatide) and 201,136 on sulfonylureas for comparison.

The cardiovascular findings are stark: